Skip to main content

Jessica Hagen

By Jessica Hagen | 02:31 pm | October 05, 2022
The astronauts will support several investigations, including ones aiming to create a protein-based artificial retina and evaluate how gut microbes change in space.
By Jessica Hagen | 03:12 pm | October 04, 2022
The alliance will expand Sanofi's trek into tech-based drug discovery and development platforms.
By Jessica Hagen | 01:41 pm | October 04, 2022
The San Francisco-based investment firm purchased bswift to propel long-term growth.
By Jessica Hagen | 02:10 pm | October 03, 2022
The UK-based wearable medical device company plans to use the funds to expand in Europe and North America.
By Jessica Hagen | 02:20 pm | September 30, 2022
The new allocation will help the company expand its insurance coverage, including Medicare and Medicaid, across the U.S.
By Jessica Hagen | 02:55 pm | September 29, 2022
A J.D. Power study indicates telehealth is the preferred method among consumers for receiving certain types of medical care.
By Jessica Hagen | 07:45 pm | September 28, 2022
Rippl's mental health offering aims to provide seniors with 24/7 access to care.
By Jessica Hagen | 02:33 pm | September 28, 2022
Kaleidoscope, Surge, Optellum, Cionic and Arcascope also announce funding rounds.
By Jessica Hagen | 11:38 am | September 28, 2022
Mati Gil, CEO of AION Labs, describes how its new startup OMEC.AI came to fruition and what it aims to accomplish for drug discovery and development. 
By Jessica Hagen | 01:54 pm | September 27, 2022
  The company’s device, Primary Relief, is the latest of DyAnsys’ long list of devices to receive FDA clearance.